search
Back to results

Incidence of Acute Laryngeal Injury Following Endotracheal Intubation

Primary Purpose

Intubation Complication

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Budesonide and Azithromycin
Placebo control of budesonide and azithromycin
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Intubation Complication focused on measuring Intubation injury, Acute laryngeal injury, Chronic Laryngeal Injury

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. English-speaking
  2. Greater than 24 hours and less than 7 days of intubation in the intensive care unit

Exclusion Criteria:

  1. Age under 18 years on admission
  2. Patients with anticipated discharge 5 days after extubation
  3. Patients who are dependent for activities of daily living (ADLs) in the 30 days prior to admission
  4. Patients unable to consent
  5. Patients with neck trauma
  6. Patients with head and neck malignancies
  7. Patients with pre-existing laryngeal or tracheal stenosis
  8. Patients with other pre-existing respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, neuromuscular dystrophies, cystic fibrosis, bronchiectasis
  9. Patients who had been previously intubated for an extended period of time
  10. Patients who are pregnant or currently breastfeeding
  11. Patients with allergies to study medications
  12. Patients with a resting heart rate greater than 100 beats per minute
  13. Patients with a prolonged corrected QT (QTc) interval (>450 msec) or the use of medications that prolong the QTc interval or are associated with Torsades de pointes (with the exception of amiodarone)24
  14. Patients with severe hearing impairment documented by audiometric testing

Sites / Locations

  • Vanderbilt University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Medical Therapy

Placebo Control

Arm Description

medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days

Placebo control medication for 14 days

Outcomes

Primary Outcome Measures

Acute Laryngeal Injury
Endoscopic examination with evidence of laryngeal injury
Chronic Obstructive Pulmonary Disease Dyspnea Questionnaire (CCQ)
12 week patient-reported dyspnea via CCQ. Total score is recorded, with a range of 0-60 with higher values representing worse outcomes.

Secondary Outcome Measures

Chronic Laryngeal Injury
In those with acute laryngeal injury, what is the incidence of chronic laryngeal injury

Full Information

First Posted
August 7, 2017
Last Updated
August 20, 2023
Sponsor
Vanderbilt University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03250975
Brief Title
Incidence of Acute Laryngeal Injury Following Endotracheal Intubation
Official Title
Incidence of Acute Laryngeal Injury Following Endotracheal Intubation
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 19, 2017 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this investigation is to delineate the incidence of acute and chronic laryngeal injury following intubation within our health system. In addition, this study seeks to identify risk factors for airway injury that may provide information to help reduce the incidence of injury or increase the speed of diagnosis through hospital based process measures. Study Aims Determine the incidence of acute laryngeal injury in patients with prolonged intubation. Determine the incidence of chronic laryngeal injury in the subset of patients with acute laryngeal injury Initiate a randomized control trial to investigate the ability of azithromycin and budesonide to improve objective and subjective breathing measures in patients with Acute Laryngeal injury (ALgI) following endotracheal intubation.
Detailed Description
In the United States, 55 000 patients receive care in more than 6 000 intensive care units (ICUs) each day. The most common reason for ICU admission is respiratory failure and the need for a mechanical ventilator. Although 50% to 70% of patients survive their acute illness, the remainder are left with massive impairments in health and overall functioning. One of the most severe post-ICU complications is airway scaring directly resulting from endotracheal intubation. Scarring of the vocal cords or trachea after intubation results from mucosal injury by an endotracheal tube (i.e. breathing tube). The initial mucosal injury ultimately heals with pathologic fibrotic contracture. This fibrosis physiologically restricts ventilation, and produces life-threatening dyspnea and airway obstruction. Acute and chronic airway injury following intubation is largely unappreciated owing to the fact that the long-term sequelae of intensive respiratory support is rarely managed by practitioners providing acute care. Treatments for chronic airway injury are suboptimal. They are largely surgical and offer marginal improvement in breathing while causing permanently worsened voice. Preventative efforts to preserve laryngeal and tracheal function (through identification of modifiable risk factors) could reduce the incidence of this devastating complication of medical care. Additionally, early identification of acute laryngeal injury after intubation may prevent the development of chronic complications. Patients with acute post-intubation airway injury treated with early endoscopic surgery require significantly fewer procedures, and may avoid an invasive open surgical reconstruction compared with patients treated with chronic fibrotic scars. The development of airway fibrosis and ventilatory obstruction has been linked to inflammatory processes. Macrolide antibiotics such as azithromycin has been shown to reduce mucosal airway inflammation. IN addition the combination of a macrolide antibiotic and budesonide an inhaled corticosteroid has been shown to work synergistically to reduce inflammation and modify the disease process of tracheal stenosis in rabbit models. The purpose of this investigation is to delineate the incidence of acute and chronic laryngeal injury following intubation within our health system. In addition, this study seeks to identify risk factors for airway injury that may provide information to help reduce the incidence of injury or increase the speed of diagnosis through hospital based process measures. Finally, in patients with acute laryngeal injury, this study seeks to investigate the effects of azithromycin and budesonide to improve objective and subjective breathing measures in patients with Acute Laryngeal injury (ALgI) following endotracheal intubation. Overview: Patients will be recruited from adult patients in the surgical and medical intensive care units of Vanderbilt Medical Center who were intubated for greater than 48 hours. Following informed consent and study enrolment, data will be stored in a secure REDCap database housed within a server located behind the Vanderbilt University Medical Center (VUMC) firewall. Data analysis will be performed by KSP at VUMC. Protocol: Within 72 hours of extubation, ICU patients will be approached for participation by study KSP (they will be clinically evaluated for the ability to provide informed consent). If they are not able to consent for themselves an LAR will be approached for consent by study KSP. Consent will be electronic, paper, or via phone. Consented and enrolled patients will undergo routine medical examination of their larynx with flexible nasolaryngoscopy after anesthetizing and decongesting the nose with 1% lidocaine mixed in oxymetazoline. During the examination, patients will be asked to sniff (which triggers opening of the vocal cords), and say "Eee" which (triggers closing). These maneuvers allow assessment of vocal fold movement. The evaluation will be recorded for subsequent blinded review. Recordings will be coded with a research identifier and stored digitally securely on a harddisk locked within the principle investigators office. If acute laryngeal injury is noted on examination, a repeat office-based examination of the larynx will be scheduled in 8 to 12 weeks. The second phase of this study will investigate the effects of azithromycin and budesonide to improve objective and subjective breathing measures in patients with Acute Laryngeal injury (ALgI) following endotracheal intubation. The consenting process for these patients will mirror the first phase. In patients with ALgI, patients will be randomized to a medical therapy group consisting azithromycin 250mg or budesonide of 0.5mg for 14 days or non-drug placebo group. This study will be double blinded. For participants, a repeat examination will be scheduled at 12 weeks and at that time patients will be asked to complete surveys (CCQ, VHI-10, SF-12). Consented patients will also have information abstracted from their medical record. Pertinent information collected will include patient-specific covariates; i.e. medical co-morbidities, laboratory values, and demographics as well as procedure-specific covariates; i.e. endotracheal tube size, length of intubation, recorded endotracheal tube cuff pressures, and the number of recorded intubation attempts. The initial and follow up examinations will be non-billable and provided no-cost to the patients. If chronic laryngeal injury is noted on follow-up examination, the patients will then be referred within the institution as a routine patient and offered standard treatment options as directed by a fellowship trained laryngologist.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intubation Complication
Keywords
Intubation injury, Acute laryngeal injury, Chronic Laryngeal Injury

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
64 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Medical Therapy
Arm Type
Experimental
Arm Description
medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days
Arm Title
Placebo Control
Arm Type
Placebo Comparator
Arm Description
Placebo control medication for 14 days
Intervention Type
Drug
Intervention Name(s)
Budesonide and Azithromycin
Intervention Description
Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
Intervention Type
Other
Intervention Name(s)
Placebo control of budesonide and azithromycin
Intervention Description
placebos of the medications will be given for 14 days in patients randomized to the control group
Primary Outcome Measure Information:
Title
Acute Laryngeal Injury
Description
Endoscopic examination with evidence of laryngeal injury
Time Frame
Within 72 hours of extubation
Title
Chronic Obstructive Pulmonary Disease Dyspnea Questionnaire (CCQ)
Description
12 week patient-reported dyspnea via CCQ. Total score is recorded, with a range of 0-60 with higher values representing worse outcomes.
Time Frame
12 week follow up
Secondary Outcome Measure Information:
Title
Chronic Laryngeal Injury
Description
In those with acute laryngeal injury, what is the incidence of chronic laryngeal injury
Time Frame
8-12 weeks after sustaining acute laryngeal injury

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: English-speaking Greater than 24 hours and less than 7 days of intubation in the intensive care unit Exclusion Criteria: Age under 18 years on admission Patients with anticipated discharge 5 days after extubation Patients who are dependent for activities of daily living (ADLs) in the 30 days prior to admission Patients unable to consent Patients with neck trauma Patients with head and neck malignancies Patients with pre-existing laryngeal or tracheal stenosis Patients with other pre-existing respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, neuromuscular dystrophies, cystic fibrosis, bronchiectasis Patients who had been previously intubated for an extended period of time Patients who are pregnant or currently breastfeeding Patients with allergies to study medications Patients with a resting heart rate greater than 100 beats per minute Patients with a prolonged corrected QT (QTc) interval (>450 msec) or the use of medications that prolong the QTc interval or are associated with Torsades de pointes (with the exception of amiodarone)24 Patients with severe hearing impairment documented by audiometric testing
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Justin R Shinn, MD
Phone
(406)531-9698
Email
justin.r.shinn@vanderbilt.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Anne S Lowery, BA
Phone
314-373-9228
Email
anne.sun@vanderbilt.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander Gelbard, MD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kate Von Wahlde, MJ, CCRP
Phone
615-322-0333
Email
kate.vonwahlde@vanderbilt.edu
First Name & Middle Initial & Last Name & Degree
Alexander Gelbard, MD
First Name & Middle Initial & Last Name & Degree
Justin Shinn, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
11445675
Citation
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10. doi: 10.1097/00003246-200107000-00002.
Results Reference
background
PubMed Identifier
26466860
Citation
Hillel AT, Karatayli-Ozgursoy S, Samad I, Best SR, Pandian V, Giraldez L, Gross J, Wootten C, Gelbard A, Akst LM, Johns MM; North American Airway Collaborative (NoAAC). Predictors of Posterior Glottic Stenosis: A Multi-Institutional Case-Control Study. Ann Otol Rhinol Laryngol. 2016 Mar;125(3):257-63. doi: 10.1177/0003489415608867. Epub 2015 Oct 14.
Results Reference
background
PubMed Identifier
25290987
Citation
Gelbard A, Francis DO, Sandulache VC, Simmons JC, Donovan DT, Ongkasuwan J. Causes and consequences of adult laryngotracheal stenosis. Laryngoscope. 2015 May;125(5):1137-43. doi: 10.1002/lary.24956. Epub 2014 Oct 7.
Results Reference
background
PubMed Identifier
32301783
Citation
Shinn JR, Campbell BR, Ely EW, Gelbard A. The authors reply. Crit Care Med. 2020 May;48(5):e431. doi: 10.1097/CCM.0000000000004301. No abstract available.
Results Reference
derived
PubMed Identifier
32205633
Citation
Shinn JR, Campbell BR, Ely EW, Gelbard A. The authors reply. Crit Care Med. 2020 Apr;48(4):e338-e339. doi: 10.1097/CCM.0000000000004253. No abstract available.
Results Reference
derived
PubMed Identifier
31634236
Citation
Shinn JR, Kimura KS, Campbell BR, Sun Lowery A, Wootten CT, Garrett CG, Francis DO, Hillel AT, Du L, Casey JD, Ely EW, Gelbard A. Incidence and Outcomes of Acute Laryngeal Injury After Prolonged Mechanical Ventilation. Crit Care Med. 2019 Dec;47(12):1699-1706. doi: 10.1097/CCM.0000000000004015.
Results Reference
derived
PubMed Identifier
31352415
Citation
Lowery AS, Kimura K, Shinn J, Shannon C, Gelbard A. Early medical therapy for acute laryngeal injury (ALgI) following endotracheal intubation: a protocol for a prospective single-centre randomised controlled trial. BMJ Open. 2019 Jul 27;9(7):e027963. doi: 10.1136/bmjopen-2018-027963.
Results Reference
derived

Learn more about this trial

Incidence of Acute Laryngeal Injury Following Endotracheal Intubation

We'll reach out to this number within 24 hrs